treatment and the slope of tumor growth on treatment) was calculated. Hyperprogression was defined as a TGKR > ¼2. Results: 40 patients have been treated Nivo (n ¼ 20) or IRI (n ¼ 20) as salvage line before March 2018. The median age was 65 years (range 37-81) in Nivo and 68 years (range 46-80) in IRI.; 11 males and 9 females in Nivo and 16 males and 4 females in IRI; PS 0/1/2 score 1/10/9 in Nivo and 10/9/1 in IRI. Twenty-eight patients (Nivo : IRI ¼ 9:19) had target lesions according to RECIST 1.1. The rate of grade3-4 IrAE were diarrhea (5%), interstitial pneumonia (5%), and mytosis (5%) in Nivo group. No treatment-related death were observed in both groups. No pseudo-progression was observed in Nivo group. Hyperprogression were observed in five patients (56%) with Nivo. On the contrary, only one patients (5%) experienced hyperprogression with IRI. Conclusion: The percentage of hyperprogression treated Nivo was higher than treated IRI in this analysis. Further analysis will be warranted.
O2 À 1 À 1 Evaluation of diarrhea as immune-related adverse event by colonoscopy Background: Immune checkpoint inhibitors (ICIs) are a type of immunotherapy used for various malignant tumors. The side effects in patients treated with ICIs are designated as an immune-related adverse event (irAE) . Diarrhea is often observed as irAE and is occasionally accompanied by severe colitis which resembles ulcerative colitis (UC) . Diarrhea in most cases is mild but when severe needs care by a gastroenterologist. In this study, we retrospectively evaluated the severity of diarrhea, treatment for it, and endoscopic findings in cases with diarrhea as irAE.
Methods: From August 2015 to December 2017, 166 cases (120 nivolumab, 38 pembrolizumab, and 8 ipilimumab) were treated in our hospital. In this study, grades 2 and 3 diarrhea which required treatment was determined to be an irAE. We analyzed the diarrhea incidence rate, examination, treatment, endoscopic findings, and pathological severity according to the Nancy histological index for UC (Gut 2017). Results: The number of patients with diarrhea was eleven (6.6%). Two were complicated by interstitial cystitis or myasthenia gravis. Among these eleven cases, colonoscopy was performed on five patients, feces culture in six, and enhanced computerized tomography (CT) in four. In one patient, bacterial colitis (Aeromonas Hydrophilia) was revealed and was consequently excluded from further analysis. Seven patients were treated with nivolumab, two with pembrolizumab, and one with ipilimumab. The number of patients in each Nancy histological index for UC grades 4/3/2/1 was 1/2/0/1, respectively. Steroid treatment was performed in ten patients (PSL15-70mg, mPSL 100mg). Three patients had diarrhea resistant to PSL treatment and were classified as grade 4 or 3 by this index.
Conclusions: In most cases, diarrhea by checkpoint inhibitors as irAE was cured by steroid treatment. Nancy histological index for UC may help predict its resistance to steroid treatment.
O2 À 2 À 3 Clarification of mechanisms of acquired resistance for afatinib using plasma samples
Tomomi Nakamura Department of Internal Medicine, Faculty of Medicine, Saga University
Background: The secondary EGFR mutation T790M is the most frequent mechanism of acquired resistance to first generation EGFR-TKI which occurred about 50-70%. Furthermore, many mechanisms of acquired resistance to osimertinib had already reported such as EGFR C797S, T790M loss, EGFR amplification, MET amplification, BRAF V600E. While the elucidation of the mechanisms of acquired resistance to first and third generation EGFR-TKI progresses, there have been few clinical investigations into the mechanisms of acquired resistance to second generation EGFR-TKIs, afatinib. Method: We analyzed 20 adenocarcinoma patients treated with afatinib. Seven patients administered afatinib as the first line EGFR-TKI treatment. Thirteen patients treated after discontinuation previous EGFR-TKI due to disease progression. We examined EGFR T790M, C797S, BRAF V600E, MET amplification by MBP-QP method and droplet digital PCR using plasma and re-biopsy samples.
Result: Three of ten patients with T790M negative before afatinib treatment turned to positive at PD to afatinib. Ten of thirteen patients already acquired T790M under the influence of previous EGFR-TKI and afatinb demonstrated two PR and three SD to the T790M positive patients. T790M is also detected from samples at PD to afatinib in all patients; T790M loss was never seen. We detected C797S in three patients and all C797S mutation was detected in patients with T790M positive. Allele frequency of C797S was very rare in all patients and two of three patients with T790M and C797S simultaneously positive patients achieved PR to osimertinib. However, PFS with T790M and C797S simultaneously positive patients was a trend shorter than PFS who detected T790M only. V600E was detected in one patient at PD to afatinib. MET amplification was never detected in this study. Conclusion: It was suggested that T790M was the major mechanism of acquired resistance to afatinib. C797S and V600E might also have participated in the acquired resistance to afatinib.
O2 À 3 À 2 Survival of transitional cell carcinoma of the bladder for Japanese patients residing in the United States Introduction: Bladder cancer is the ninth most common cancer in the world. Transitional cell carcinoma of the bladder (TCC) is the most frequent urinary tract malignancy. Recent medical advances led to a generally improved survival of cancer patients, and an increase in their chance of getting a second primary malignancy. The aim of this study is to investigate the effect of prior malignancies on the survival in bladder transitional cell carcinoma patients. 
